SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending after its latest earnings report, which revealed a revenue miss largely driven by a sharp decline in crypto trading volume, despite an EPS beat. The community is divided, with some viewing the dip as a long-term buying opportunity due to new product initiatives like prediction markets, while others raise concerns over valuation and slowing growth.

Lyft, Inc. engages in the provision and management of an online social rideshare community platform. It offers access to a network of shared bikes and scooters for shorter rides and first mile and last-mile legs of multimodal trips, information about nearby public transit routes, and Lyft Rentals to offer riders a view of transportation options when planning any trip. The company was founded by Marcus Cohn, John Zimmer, Rajat Suri, Matt van Horn, and Logan Green in 2007 and is headquartered in San Francisco, CA.

Lyft Inc - Ordinary Shares Cls A

Lyft Inc

Lyft is trending amidst a post-earnings sell-off, with discussions centered on its Q4 revenue miss and Q1 guidance, despite an EPS beat from a tax benefit and a newly authorized $1 billion share buyback; the community debates whether this reflects an overreaction or deep-seated concerns about autonomous vehicle disruption and competitive positioning against Uber.

Mattel, Inc. engages in the ownership of children's and family entertainment franchises. It operates through the following segments: North America, International, and American Girl. The North America and International segments focus on marketing and selling toys and consumer products. The American Girl segment includes marketing, retailing, and publishing dedicated to its mission to help girls grow up with confidence and character. The company was founded by Elliot Handler, Ruth Handler, and Harold Matson in 1945 and is headquartered in El Segundo, CA.

Mattel, Inc.

Mattel experienced a dramatic sell-off, with its stock hitting both a 52-week high and low in the same day, after reporting a Q4 earnings miss and a weaker FY26 profit outlook. While some are shocked by the decline, a significant portion of the community views the reaction as "overdone" and is "loading up" on what they perceive as a discounted buying opportunity, alongside news of the company acquiring full ownership of its Mattel163 mobile game studio.

Shopify, Inc. is a global commerce company that provides essential internet infrastructure for commerce, offering trusted tools to start, scale, market, and run a retail business of any size. The Company's software enables merchants to run their business across all of their sales channels, including web and mobile storefronts, physical retail locations, social media storefronts and marketplaces. The Shopify platform provides merchants with a single view of their business across all of their sales channels and enables them to manage products and inventory, process orders and payments, fulfill and ship orders, build customer relationships, source products, leverage analytics and reporting and access financing, all from one integrated back office. The company was founded on September 28, 2004 and is headquartered in Ottawa, Canada.

Shopify Inc - Ordinary Shares - Class A (Sub Voting)

Shopify Inc

Shopify is drawing significant attention ahead of its imminent earnings report, fueling a strong debate among investors as many anticipate a powerful rebound driven by robust holiday sales and AI integration benefits, while others remain cautious about its high valuation amid a broader software sector pullback.

Ford Motor Co. engages in the manufacture, distribution, and sale of automobiles. It operates through the following segments: Ford Blue, Ford Model E, Ford Pro, Ford Next, Ford Credit, and Corporate Other. The Ford Blue, Ford Model E, and Ford Pro segment includes the sale of Ford and Lincoln vehicles, service parts, and accessories, together with the associated costs to develop, manufacture, distribute, and service the vehicles, parts, and accessories. The Ford Next segment is involved in the expenses and investments for emerging business initiatives aimed at creating value for Ford in vehicle-adjacent market segments. The Ford Credit segment consists of the Ford Credit business on a consolidated basis, which is primarily vehicle-related financing and leasing activities. The Corporate Other segment refers to corporate governance expenses, past service pension and OPEB income and expense, interest income and gains and losses from cash, cash equivalents, and marketable securities, and foreign exchange derivatives gains, and losses associated with intercompany lending. The company was founded by Henry Ford on June 16, 1903 and is headquartered in Dearborn, MI.

Ford Motor Co.

Ford Motor Co

Ford is actively trending after its Q4 earnings revealed a substantial net loss due to EV restructuring, but community discussion is primarily focused on the encouraging 2026 adjusted EBIT outlook and strong hybrid sales, which appear to be outweighing immediate performance concerns.

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.

Nektar Therapeutics

Nektar Therapeutics is trending following strong 52-week data for its atopic dermatitis drug, rezpegaldesleukin, which demonstrated durable and deepening responses, leading analysts to raise price targets and sparking community excitement over its competitive potential against Dupixent. Despite a recent public offering and mixed past results for alopecia areata, the drug's favorable safety profile and significant market opportunity are key discussion points, fueling speculation of a major pharmaceutical buyout.

The Charles Schwab Corp. is a savings and loan holding company, which engages in the provision of wealth management, securities brokerage, banking, asset management, custody, and financial advisory services. It operates through the Investor Services and Advisor Services segments. The Investor Services segment includes retail brokerage, investment advisory, and banking and trust services to individual investors, retirement plan and business services, as well as other corporate brokerage services, to businesses and employees. The Advisor Services segment provides custodial, trading, banking and trust, and support services to independent registered investment advisors, independent retirement advisors, and recordkeepers. The company was founded by Charles Robert Schwab in 1986 and is headquartered in Westlake, TX.

Charles Schwab Corp.

The financial services sector's reaction to new AI-powered tax planning tools from competitors is driving conversation around Charles Schwab, with the community debating the potential for disruption to traditional advisory models and viewing the sharp sell-off as a significant overreaction.

Cloudflare, Inc. engages in the provision of cloud-based services to secure websites. It offers various products for performance and reliability, video streaming and delivery, advanced security, insights, Cloudflare for developers, domain registration, and Cloudflare marketplace. It operates through the United States and Rest of the World geographical segments. The company was founded by Matthew Prince, Michelle Zatlyn, and Lee Holloway in July 2009 and is headquartered in San Francisco, CA.

Cloudflare Inc - Ordinary Shares - Class A

Cloudflare Inc

Cloudflare is trending due to a strong earnings beat and robust revenue guidance, with its CEO emphasizing the company's critical role as the "backbone of the agentic internet" amid surging AI demand, distinguishing its performance during a broader software sector downturn.

Lattice Semiconductor Corp. engages in the business of developing technologies that are monetized through differentiated programmable logic semiconductor products, system solutions, design services, and licenses. It also offers silicon-based and silicon-enabling products, evaluation boards, development hardware, and related intellectual property licensing, services, and sales. The company was founded in 1983 and is headquartered in Hillsboro, OR.

Lattice Semiconductor Corp.

Lattice Semiconductor is trending following its Q4 earnings, which showed a revenue beat and a strong forecast for the next quarter, exciting the community with significant options gains. Investors are keenly watching its momentum in AI, data centers, and its pivotal role in edge computing and robotics, though some anticipate profit-taking.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals is generating buzz due to observed large after-hours trading volumes and the imminent closure of its Astria Therapeutics acquisition, driving community debate over potential short covering and a long-awaited reversal, contrasting with ongoing investor frustration over sustained share price pressure and dilution concerns.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Likely ETF Winners & Losers From Winter Storm Fern

Winter Storm Fern rattles the United States, lifting heating demand and natural gas prices as UNG stands out while airlines and consumers face headwinds.

<ul class="summary-bullets"><li>Oppenheimer downgraded Mosaic to ‘Perform’ from ‘Outperform’.</li><li>Tight sulfur market conditions are expected to persist into the first half of 2026, continuing to weigh on Mosaic’s outlook, the brokerage firm added.</li><li>Tight credit and increased competition due to an influx of lower-grade phosphate imports from China weighed on demand and margins in Brazil.</li></ul>Mosaic Company (MOS) shares were trading down 4.5% on Friday after the firm said that fertilizer market conditions remained challenging in the fourth quarter (Q4) of 2025, as weaker-than-usual seasonal demand weighed on results.In response, Oppenheimer downgraded Mosaic to ‘Perform’ from ‘Outperform’ and removed the firm’s previous $35 price target following the company’s “weak” preliminary Q4 results.Oppenheimer expects Mosaic to continue making gradual progress on operating rates, but noted there is no clear catalyst to lift fertilizer demand in the current crop year. Tight sulfur market conditions are also expected to persist into the first half of 2026, continuing to weigh on the outlook.Despite the intraday drop, retail sentiment on Stocktwits remained in the ‘bullish’ zone over the past 24 hours.<h2 class="st-heading-2">Q4 Preliminary Update</h2>In North America, fertilizer demand dropped sharply as growers remained under economic pressure and an early winter shortened the fall application season. Phosphates were hit hardest due to lower affordability than potash, with shipments estimated to be down about 20% from a year ago.The weak environment weighed on Mosaic’s results, with Q4 phosphate sales of about 1.3 million tonnes and potash sales near 2.2 million tonnes. In response, the company adjusted its phosphate production and shifted volumes to markets showing stronger demand, keeping overall output in line with the prior quarter, though lower sales and rising inventories pressured cash flow.Conditions in Brazil also worsened, as tighter credit and increased competition, due to an influx of lower-grade phosphate imports from China, weighed on demand and margins. As a result, Mosaic Fertilizantes’ sales fell short of expectations, even as full-year volumes were roughly flat.Looking ahead, Mosaic sees a more favorable setup in 2026, supported by nutrient replenishment needs, government support programs, tightening phosphate markets, and reduced Chinese exports, all of which could help lift demand and prices over time, it said.The company is expected to post its Q4 2025 results on February 24.Over the past year, <a href="https://stocktwits.com/symbol/MOS">MOS stock</a> has declined nearly 2%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-abus-stock-fall-today/cmUlzXeR4BY">ABUS Stock On Track For Biggest Intraday Drop In Over 5 Years – What’s The Issue Around Its Patent In Europe?</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Mosaic Company logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

MOS Stock Sees Red As Cheaper Chinese Imports Weigh On Q4 Operations

Mosaic Company said that fertilizer market conditions remained challenging in the fourth quarter, as weaker-than-usual seasonal demand weighed on results.

Equity

Mosaic Company said that fertilizer market conditions remained challenging in the fourth quarter, as weaker-than-usual seasonal demand weighed on results.


3 Basic Materials Funds to Buy as Cyclical Tailwinds Build

FSDPX, FKRCX and ACGGX stand out as materials funds as cyclical tailwinds, pricing power and commodity demand point to a stronger 2026.

Should You Invest in the State Street Materials Select Sector SPDR ETF (XLB)?

Top-Ranked ETFs to Power Your Portfolio Higher 

With market tailwinds building and optimism returning, these top-ranked ETFs can help investors capture momentum safely.

Notable ETF Outflow Detected - XLB, NEM, ECL, NUE

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Materials Select Sector SPDR Fund (Symbol: XLB) where we have...

Noteworthy ETF Outflows: XLB, ECL, MLM, FCX

See Which Of The Latest 13F Filers Holds XLY

At Holdings Channel, we have reviewed the latest batch of the 20 most recent 13F filings for the 09/30/2025 reporting period, and noticed that The Materials Select Sector SPDR Fund (Symbol: XLY) was...

US Food and Drug Administration Commissioner Marty Makary said he’s “taking a hard look” at whether Sarepta Therapeutics’ gene therapy, Elevidys, should remain on the market, following recent patient deaths involving the treatment.&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="http://stockwits.com/symbol/SRPT">Sarepta’s stock</a> plummeted more than 26% in midday trade on Friday. However, on Stocktwits, retail sentiment around the company remained in ‘extremely bullish’ territory amid ‘extremely high’ levels of chatter.A separate&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-request-sarepta-stop-all-shipments-gene-therapy-elevidys-source-says-2025-07-18/#:~:text=The%20FDA's%20request%20follows%20the,condition%20called%20Duchenne%20muscular%20dystrophy.">report</a> by Reuters said that the FDA plans to request Sarepta to stop all shipments of Elevidys voluntarily.Makary’s comments during an&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-07-18/fda-is-investigating-if-sarepta-s-elevidys-should-stay-on-market">interview</a> with Bloomberg come after the company on Thursday disclosed a&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sarepta-draws-wall-street-ire-after-third-patient-death-this-year/ch8kMF7R5qY">third patient death</a> in a clinical trial involving a different experimental gene therapy that uses a similar viral delivery system.&nbsp;A company spokesperson&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-07-18/sarepta-says-another-patient-died-after-receiving-gene-therapy">told</a> Bloomberg that a 51-year-old patient died of acute liver failure last month in an early-stage trial of a gene therapy to treat limb-girdle muscular dystrophy.The FDA had already been investigating two earlier deaths linked to Elevidys.The growing number of fatalities is raising questions about the future of Sarepta’s therapies and the regulatory path for gene treatments that use adeno-associated viral (AAV) vectors. Elevidys, which was granted accelerated approval in 2023 for Duchenne muscular dystrophy, has remained on the market under post-approval study requirements.Bloomberg also reported that the latest death resulted in an unusually tense exchange between analysts and Sarepta executives on a Friday call. The same group of analysts reportedly had a call with the company earlier this week about the future of Elevidys, but the firm failed to disclose the third patient death. On Friday, two of the analysts asked executives whether the company was keeping any other fatalities undisclosed.“We are historically a very transparent organization,” said Sarepta CEO Douglas Ingram, according to the report, adding that the company didn’t disclose the third patient death earlier because “it was neither material nor central” to what was being discussed.&nbsp;Sarepta’s stock is down 88% year-to-date and nearly 90% over the past 12 months.Get updates to this developing story directly on Stocktwits.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/grubhub-owner-wonder-reportedly-in-talks-for-500-m-debt-refinancing/ch8kHoKR5qp">Grubhub Owner Wonder Reportedly In Talks For $500M Debt Refinancing</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Sarepta Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

FDA Is Reportedly ‘Taking A Hard Look’ To Evaluate Whether Sarepta’s Gene Therapy Elevidys Should Remain On The Market

The FDA had already been investigating two earlier deaths linked to Elevidys.

President Donald Trump’s confirmation of a 50% tariff on copper imports sent U.S. copper futures and mining stocks – including Freeport-McMoran (FCX) and Southern Copper (SCCO) – sharply higher Tuesday. He also said that tariffs targeting the pharmaceutical and semiconductor sectors would be next on the docket.“We’re going to be announcing pharmaceuticals, chips, and various couple of other things — big one,” Trump told reporters at a White House cabinet meeting. “Now today we’re doing copper… I believe the tariff on copper, we’re going to make it 50%.”U.S. copper futures jumped more than 10% on the news, while&nbsp;<a href="http://stocktwits.com/symbol/FCX">Freeport-McMoran’s stock</a> rallied nearly 5%. On Stocktwits, retail sentiment around Freeport-McMoRan edged higher within ‘bullish’ territory as chatter jumped to ‘high’ levels from ‘normal’ a day ago.&nbsp;<a href="http://stocktwits.com/symbol/SCCO">Southern Copper’s stock</a> also gained more than 1% following the announcement, and&nbsp;In February, the Trump administration launched a Section 232 investigation into copper imports, citing potential national security concerns. That probe is due to conclude by November.During the cabinet meeting, Agriculture Secretary Brooke Rollins also raised alarms about Chinese ownership of U.S. farmland, calling it a “massive national security issue.”&nbsp;She said China has been acquiring land near U.S. military bases and urged Congress to ban such purchases. “There’s an executive order coming and some other things coming behind that,” she added.Despite the tough stance on trade and foreign investment, Trump said U.S.-China relations remain stable. “They’ve been very fair on our trade deal, honestly,” he said, adding that he maintains regular communication with Chinese President Xi Jinping. “I’m getting along with President Xi very well. We speak often.”Markets remained mixed after Trump’s cabinet meeting. The&nbsp;<a href="http://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a> edged 0.05% higher, while the&nbsp;<a href="http://stocktwits.com/symbol/DIA">SPDR Dow Jones Industrial Index ETF (DIA)</a> remained down by 0.27%. Meanwhile, the&nbsp;<a href="http://stocktwits.com/symbol/QQQ">Invesco QQQ Trust Series 1 (QQQ)</a>, which tracks the tech-heavy Nasdaq 100, gained 0.2%.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-says-eu-trade-deal-two-days-off-predicts-300-b-tariff-revenue/chFvyNrR5WM">Trump Says EU Trade Deal ‘Two Days Off’, Predicts $300B In Tariff Revenue By Year-End</a>

U.S. President Donald Trump speaks to members of the press during a Cabinet Meeting at the White House on July 08, 2025 in Washington, DC. (Photo by Andrew Harnik/Getty Images)

Copper Prices Surge After Trump Says 50% Tariff Is Coming – Pharma And Chip Levies Next

President Donald Trump also said U.S.-China relations remain stable and that he’s getting along with Chinese President Xi Jinping “very well.” 

SSgA Active Trust - State Street Materials Select Sector SPDR ETF

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $SHOP earnings on Wednesday?

Current Price	$52.91
Prev Close	$52.18
Open	$52.15
Dividend Yield	N/A
50-Day Moving Average	$47.14
Beta	N/A
Avg. Volume	16.24M
PE Ratio	N/A

52-Week High	$52.31
52-Week Low	$36.56
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

XLB
Materials Select Sector SPDR Fund

Feed

News

Sentiment

Fundamentals

Info

Latest XLB News

XLBMaterials Select Sector SPDR Fund